Valeos Pharma A/S, a leading Danish producer of EU GMP-certified medical cannabis, has entered into a strategic partnership with Celadon Pharmaceuticals Plc, a publicly listed UK-based pharmaceutical company specializing in cannabis-based medicines. This collaboration aims to accelerate the production and increase the supply of high-THC medical cannabis across Europe.
As part of the agreement, Valeos will leverage Celadon's advanced cannabis genetics and proprietary cultivation techniques to enhance the yield and quality of its production. The collaboration is expected to significantly boost Valeos’ production capacity at its EU-GMP certified facility in Holeby, Denmark, from 1.5 to up to 4.5-6 tons annually. The cannabis supplied from Valeos to Celadon will have the potential to generate up to £30 million worth of pharmaceutical-grade medical cannabis per year, an according to an estimate from Celadon.
This partnership strengthens Valeos' position in the growing European market for phytopharmaceuticals and aligns with its commitment to playing a key role in the supply of high-quality medical cannabis products to patients across Europe.
For more details, please refer to:
コメント